JP2012506898A - ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤とｍＴＯＲ阻害剤との併用剤 - Google Patents

ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤とｍＴＯＲ阻害剤との併用剤 Download PDF

Info

Publication number
JP2012506898A
JP2012506898A JP2011533721A JP2011533721A JP2012506898A JP 2012506898 A JP2012506898 A JP 2012506898A JP 2011533721 A JP2011533721 A JP 2011533721A JP 2011533721 A JP2011533721 A JP 2011533721A JP 2012506898 A JP2012506898 A JP 2012506898A
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
mtor
hydrogen
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011533721A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012506898A5 (cg-RX-API-DMAC7.html
Inventor
ガルシア−エチェベリア，カルロス
マイラ，サウバー−ミシェル
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2012506898A publication Critical patent/JP2012506898A/ja
Publication of JP2012506898A5 publication Critical patent/JP2012506898A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011533721A 2008-10-31 2009-10-29 ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤とｍＴＯＲ阻害剤との併用剤 Withdrawn JP2012506898A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08168044 2008-10-31
EP08168044.9 2008-10-31
PCT/EP2009/064274 WO2010049481A1 (en) 2008-10-31 2009-10-29 Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014181069A Division JP2015013883A (ja) 2008-10-31 2014-09-05 ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤とｍＴＯＲ阻害剤との併用剤

Publications (2)

Publication Number Publication Date
JP2012506898A true JP2012506898A (ja) 2012-03-22
JP2012506898A5 JP2012506898A5 (cg-RX-API-DMAC7.html) 2012-12-06

Family

ID=40332588

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2011533721A Withdrawn JP2012506898A (ja) 2008-10-31 2009-10-29 ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤とｍＴＯＲ阻害剤との併用剤
JP2014181069A Withdrawn JP2015013883A (ja) 2008-10-31 2014-09-05 ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤とｍＴＯＲ阻害剤との併用剤
JP2016134514A Ceased JP2017002058A (ja) 2008-10-31 2016-07-06 ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤とｍＴＯＲ阻害剤との併用剤
JP2018136756A Pending JP2018197243A (ja) 2008-10-31 2018-07-20 ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤とｍＴＯＲ阻害剤との併用剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014181069A Withdrawn JP2015013883A (ja) 2008-10-31 2014-09-05 ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤とｍＴＯＲ阻害剤との併用剤
JP2016134514A Ceased JP2017002058A (ja) 2008-10-31 2016-07-06 ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤とｍＴＯＲ阻害剤との併用剤
JP2018136756A Pending JP2018197243A (ja) 2008-10-31 2018-07-20 ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤とｍＴＯＲ阻害剤との併用剤

Country Status (12)

Country Link
US (3) US20110195966A1 (cg-RX-API-DMAC7.html)
EP (1) EP2349275B1 (cg-RX-API-DMAC7.html)
JP (4) JP2012506898A (cg-RX-API-DMAC7.html)
KR (1) KR20110090911A (cg-RX-API-DMAC7.html)
CN (2) CN102202668A (cg-RX-API-DMAC7.html)
AU (1) AU2009309616B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0921802A8 (cg-RX-API-DMAC7.html)
CA (1) CA2736361C (cg-RX-API-DMAC7.html)
ES (1) ES2627677T3 (cg-RX-API-DMAC7.html)
MX (1) MX2011004585A (cg-RX-API-DMAC7.html)
RU (2) RU2538683C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010049481A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016518383A (ja) * 2013-05-01 2016-06-23 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ビヘテロアリール化合物及びその使用

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048914A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
WO2010056754A2 (en) 2008-11-11 2010-05-20 The Board Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
BRPI1008745A2 (pt) 2009-02-05 2019-09-17 Tokai Pharmaceuticals Inc pró-fármacos de inibidores esteroidais de cyp17/antiandrogênios
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US10391059B2 (en) 2009-11-11 2019-08-27 Rapamycin Holdings, Inc. Oral rapamycin nanoparticle preparations and use
GB2478556A (en) * 2010-03-09 2011-09-14 Myrovlytis Technology Ventures Ltd A composition for use in the treatment of Birt-Hogg-Dubô sydrome
ES2570183T3 (es) * 2011-02-16 2016-05-17 Novartis Ag Combinaciones de agentes terapéuticos para uso en el tratamiento de enfermedades neurodegenerativas
CN106619647A (zh) * 2011-02-23 2017-05-10 因特利凯有限责任公司 激酶抑制剂的组合及其用途
BR112013022697A2 (pt) * 2011-03-07 2019-09-24 Fond Telethon inibidores de fosforilação de tfeb e usos dos mesmos
NZ615593A (en) * 2011-04-25 2015-05-29 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
EP2705181B1 (en) * 2011-05-04 2016-12-21 Intellikine, LLC Combination pharmaceutical compositions and uses thereof
EP2771337B1 (en) 2011-09-27 2017-08-02 Novartis AG 3-(pyrimidin-4-yl)-oxazolidin-2-ones as inhibitors of mutant idh
CN106924741A (zh) * 2011-11-08 2017-07-07 因特利凯有限责任公司 使用多种药剂的治疗方案
CN104363914A (zh) 2011-11-23 2015-02-18 因特利凯有限责任公司 使用mTOR抑制剂的增强的治疗方案
UY34632A (es) * 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
RU2012112128A (ru) * 2012-03-29 2013-10-10 Холин Максим Николаевич ИНГИБИТОРЫ СИГНАЛЬНОГО ПУТИ PI3K/AKT/IKK/NF-kB, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ВИРУСНЫХ ЗАБОЛЕВАНИЙ
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
CN105682662A (zh) 2013-03-14 2016-06-15 马里兰大学巴尔的摩校区 雄激素受体减量调节剂及其用途
AU2014229313B2 (en) 2013-03-14 2016-07-28 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
MX2015011899A (es) 2013-03-15 2016-05-05 Genentech Inc Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
BR112016002970A2 (pt) 2013-08-12 2017-09-12 Tokai Pharmaceuticals Inc biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
CN103483345B (zh) * 2013-09-25 2016-07-06 中山大学 Pi3k激酶抑制剂、包含其的药物组合物及其应用
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
EP3708680B8 (en) 2015-04-15 2023-08-30 University of Massachusetts Compositions and methods for xi chromosome reactivation
US10576076B2 (en) 2015-05-20 2020-03-03 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
US10441584B2 (en) 2016-11-23 2019-10-15 Novartis Ag Methods of enhancing immune response
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
KR20210158019A (ko) 2020-06-23 2021-12-30 주식회사 온코빅스 포스파티딜이노시톨 3-키나제(pi3k) 억제제로써 pten 과오종 증후군에 의한 종양 세포의 성장 또는 증식을 억제하는데 유용한 신규한 피리미딘 유도체 및 이의 약제학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 약제학적 조성물
CN112294967A (zh) * 2020-09-30 2021-02-02 四川大学 一种mTOR抑制剂与抗癌药物的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044453A1 (en) * 2004-10-13 2006-04-27 Wyeth Analogs of 17-hydroxywortmannin as pi3k inhibitors
WO2007084786A1 (en) * 2006-01-20 2007-07-26 Novartis Ag Pyrimidine derivatives used as pi-3 kinase inhibitors
WO2007120897A2 (en) * 2006-04-13 2007-10-25 The Trustees Of Columbia University In The City Of New York Compositions and intraluminal devices for inhibiting vascular stenosis
WO2008098058A1 (en) * 2007-02-06 2008-08-14 Novartis Ag Pi 3-kinase inhibitors and methods of their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL153474A0 (en) * 2000-06-26 2003-07-06 Stressgen Biotechnologies Corp Human papilloma virus treatment
US20080200486A1 (en) * 2005-07-20 2008-08-21 Heidi Lane Combination Of Organic Compounds
CA2628920C (en) * 2005-11-22 2015-12-29 Kudos Pharmaceuticals Limited Pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
WO2007087395A2 (en) * 2006-01-25 2007-08-02 Osi Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
WO2008103636A1 (en) * 2007-02-20 2008-08-28 Novartis Ag Imidazoquinolines as dual lipid kinase and mtor inhibitors
EP2231147A2 (en) * 2007-12-13 2010-09-29 Novartis AG Combinations of therapeutic agents for treating cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044453A1 (en) * 2004-10-13 2006-04-27 Wyeth Analogs of 17-hydroxywortmannin as pi3k inhibitors
WO2007084786A1 (en) * 2006-01-20 2007-07-26 Novartis Ag Pyrimidine derivatives used as pi-3 kinase inhibitors
WO2007120897A2 (en) * 2006-04-13 2007-10-25 The Trustees Of Columbia University In The City Of New York Compositions and intraluminal devices for inhibiting vascular stenosis
WO2008098058A1 (en) * 2007-02-06 2008-08-14 Novartis Ag Pi 3-kinase inhibitors and methods of their use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6013062547; Ｃａｎｃｅｒ　Ｒｅｓ Ｖｏｌ．６５，　Ｎｏ．１６, 2005, ｐ．７０５２-７０５８ *
JPN6013062550; Ｃａｎｃｅｒ　Ｒｅｓ Ｖｏｌ．６８，　Ｎｏ．２０, 2008, ｐ．８３６１-８３６８ *
JPN6013062553; ＩＪＢＣＢ Ｖｏｌ．３９, 2007, ｐ．２０６-２１９ *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10028954B2 (en) 2013-04-30 2018-07-24 Genentech, Inc. Biheteroaryl compounds and uses thereof
JP2016518383A (ja) * 2013-05-01 2016-06-23 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ビヘテロアリール化合物及びその使用
JP2018035187A (ja) * 2013-05-01 2018-03-08 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ビヘテロアリール化合物及びその使用
US10010549B2 (en) 2013-05-01 2018-07-03 Genentech, Inc. Biheteroaryl compounds and uses thereof
USRE47848E1 (en) 2013-05-01 2020-02-11 Genentech, Inc. Biheteroaryl compounds and uses thereof
JP2020079264A (ja) * 2013-05-01 2020-05-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ビヘテロアリール化合物及びその使用
US11129832B2 (en) 2013-05-01 2021-09-28 Genentech, Inc. Biheteroaryl compounds and uses thereof

Also Published As

Publication number Publication date
CN102202668A (zh) 2011-09-28
RU2014115188A (ru) 2015-10-20
RU2011121508A (ru) 2012-12-10
EP2349275B1 (en) 2017-03-08
BRPI0921802A8 (pt) 2018-03-13
JP2018197243A (ja) 2018-12-13
JP2015013883A (ja) 2015-01-22
EP2349275A1 (en) 2011-08-03
AU2009309616A2 (en) 2011-07-07
AU2009309616B2 (en) 2014-02-13
US20110195966A1 (en) 2011-08-11
JP2017002058A (ja) 2017-01-05
RU2538683C2 (ru) 2015-01-10
KR20110090911A (ko) 2011-08-10
US20180133226A1 (en) 2018-05-17
CA2736361C (en) 2017-10-10
ES2627677T3 (es) 2017-07-31
CA2736361A1 (en) 2010-05-06
US20160136175A1 (en) 2016-05-19
CN105030784A (zh) 2015-11-11
BRPI0921802A2 (pt) 2016-09-27
MX2011004585A (es) 2011-06-01
AU2009309616A1 (en) 2010-05-06
WO2010049481A1 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
JP2018197243A (ja) ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤とｍＴＯＲ阻害剤との併用剤
EP2370076B1 (en) Pharmaceutical combination comprising a Hsp 90 inhibitor and a mTOR inhibitor
AU2016202372B2 (en) Combination of a phosphatidylinositol-3-kinase (PI3K) inhibitor and a mTOR inhibitor
AU2011240001B2 (en) Combination of organic compounds
KR20120079163A (ko) 피리미딜아미노벤즈아미드와 ｍｔｏｒ 키나제 억제제의 조합물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140317

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140905

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140912

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20140918